Αποτελέσματα αναζήτησης - "миелотоксичность"

1

Academic Journal

Коррекция цитостатической миелотоксичности экстрактом культуры клеток болиголова пятнистого

Πηγή: Вестник СурГУ. Медицина. 2023. Т. 16, № 1. С. 77-82

Θεματικοί όροι: миелотоксичность, экстракт культуры клеток болиголова пятнистого, клеточные культуры, применение, болиголов пятнистый, цисплатин

Σύνδεσμος πρόσβασης: https://vital.lib.tsu.ru/vital/access/manager/Repository/koha:001129655

View record at OpenAIRE

2

Academic Journal

Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer ; Профилактика нейтропении как важный фактор успешной химиотерапии злокачественных опухолей головы и шеи

Συγγραφείς: L. G. Babicheva, S. O. Podvyaznikov, Л. Г. Бабичева, С. О. Подвязников

Πηγή: Head and Neck Tumors (HNT); Том 11, № 3 (2021); 72-82 ; Опухоли головы и шеи; Том 11, № 3 (2021); 72-82 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2021-11-3

Θεματικοί όροι: эмпэгфилграстим, hematologic toxicity, myelotoxicity, febrile neutropenia, granulocyte colony-stimulating factor, filgrastim, empegfilgrastim, гематологическая токсичность, миелотоксичность, фебрильная нейтропения, гранулоцитарный колониестимулирующий фактор, филграстим

Περιγραφή αρχείου: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/675/491; Nguyen-Tan P.F., Zhang Q., Ang K.K. et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014;32(34):3858–66. DOI:10.1200/JCO.2014.55.3925.; Bonadonna G., Moliterni A., Zambetti M. et al. 30 years’ follow up of randomized study of adjuvant CMF in operable breast cancer: cogort study. BMJ 2005;330:217–20. DOI:10.1136/bmj.38314.622095.8F.; Сакаева Д.Д., Курмуков И.А., Орлова Р.В., Шабаева М.М. Практические рекомендации по диагностике и лечению фебрильной нейтропении. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2 2020;10(39). Доступно по: https://www.rosoncoweb.ru/standarts/RUSSCO/2020/2020-39.pdf. DOI:10.18027/2224-5057-2020-10-3s2-39/; Weycker D., Barron R., Edelsberg J. et al. Risk and consequences of chemotherapyinduced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res 2014;14:189. DOI:10.1186/1472-6963-14-189.; Cornes P., Gascon P., Chan S. et al. Systematic review and meta-analysis of short-versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia Adv Ther 2018;35(11):1816–29. DOI:10.1007/s12325-018-0798-6.; Криворотько П.В., Бурдаева О.Н., Ничаева М.Н. и др. Эффективность и безопасность препарата Экстимия® (эмпэгфилграстим) у пациентов с диагнозом «рак молочной железы», получающих миелосупрессивную химиотерапию: результаты двойного слепого сравнительного клинического исследования III фазы. Современная онкология 2015;17(2):45–52.; Wang Y., Chen L., Liu F. et al. Efficacy and tolerability of granulocyte colonystimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis. Sci Rep 2019;9(1):15374. DOI:10.1038/s41598-019-51982-4.; Нестерова Е.С., Клиточенко Т.Ю., Глонина Н.Н. и др. Промежуточные результаты многоцентрового ретроспективно-проспективного наблюдательного пострегистрационного исследования безопасности и эффективности применения препарата Экстимия ЗАО «Биокад» у пациентов с лимфопролиферативными заболеваниями, получающих цитотоксическую терапию. Современная онкология 2020;22(4):77–84. DOI:10.26442.18151434.2020.4.200492.; Lyman G.H., Dale D.C., Culakova E. et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013;24(10):2475–84. DOI:10.1093/annonc/mdt226.; Kuderer N.M., Dale D.C., Crawford J., Lyman G.H. Impact of primary prophylaxis with granulocyte colonystimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25(21):3158–67. DOI:10.1200/JCO.2006.08.8823.; Crawford J., Ozer H., Stoller R. et al. Reduction by granulocyte colonystimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–70. DOI:10.1056/NEJM199107183250305.; Pettengell R., Gurney H., Radford J.A. et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992;80(6):1430–6.; Trillet-Lenoir V., Green J., Manegold C. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A(3):319–24. DOI:10.1016/0959-8049(93)90376-q.; Zinzani P.L., Pavone E., Storti S. et al. Randomized trial with or without granulocyte colonystimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood 1997;89(11):3974–9.; Fossa S.D., Kaye S.B., Mead G.M. et al. Filgrastim during combination chemotherapy of patients with poorprognosis metastatic germ cell malignancy: European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16(2):716–24. DOI:10.1200/JCO.1998.16.2.716.; Doorduijn J.K., van der Holt B., van Imhoff G.W. et al. CHOP compared with CHOP plus granulocyte colonystimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003;21(16):3041–50. DOI:10.1200/JCO.2003.01.076.; Osby E., Hagberg H., Kvaloy S. et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101(10):3840–8. DOI:10.1182/blood-2002-10-3238.; Timmer-Bonte J.N., de Boo T.M., Smit H.J. et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study. J Clin Oncol 2005;23(31):7974–84. DOI:10.1200/JCO.2004.00.7955.; Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13(7):1564–71. DOI:10.1200/jco.1995.13.7.1564.; Bui B.N., Chevallier B., Chevreau C. et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13(10):2629–36. DOI:10.1200/JCO.1995.13.10.2629.; Gisselbrecht C., Haioun C., Lepage E. et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive nonHodgkin’s lymphoma: factors influencing chemotherapy administration – Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma 1997;25(3–4):289–300. DOI:10.3109/10428199709114168.; Gatzemeier U., Kleisbauer J.P., Drings P. et al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23(4):393–400.; Vogel C.L., Wojtukiewicz M.Z., Carroll R.R. et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebocontrolled phase III study. J Clin Oncol 2005;23(6):1178–84. DOI:10.1200/JCO.2005.09.102.; Su Y.B., Vickers A.J., Zelefsky M.J. et al. Double-blind, placebo-controlled, randomized trial of granulocytecolony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Avaliable at: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.487.9730&rep=rep1&type=pdf.; Gawade P., Li S., Henry D. et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy Suppor Care Cancer 2020:28(9):4413–24. DOI:10.1007/s00520-020-05295-2.; Linot B., Augereau P., Breheret R., Laccourreye L., Capitain O. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Cancer 2014;22(10):2831–7. DOI:10.1007/s00520-014-2270-8.; https://ogsh.abvpress.ru/jour/article/view/675

Διαθεσιμότητα: https://ogsh.abvpress.ru/jour/article/view/675
https://doi.org/10.17650/2222-1468-2021-11-3-72-82

View record from BASE

3

Academic Journal

Pharmacologic correction of paclitaxel induced gene- and myelotoxicity with an extract of the hairy root culture from Scutellaria baicalensis

Συγγραφείς: O. V. Neupokoeva, T. I. Fomina, O. L. Voronova, L. A. Ermolaeva, M. V. Filonova, E. P. Fedorova, A. A. Churin

Πηγή: Russian journal of genetics : Applied research. 2017. Vol. 7, № 2. P. 191-194

Θεματικοί όροι: 0301 basic medicine, миелосупрессия, 0303 health sciences, 03 medical and health sciences, миелотоксичность, шлемник байкальский, паклитаксел

Σύνδεσμος πρόσβασης: https://link.springer.com/article/10.1134/S2079059717020095
http://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000581892

View record at OpenAIRE

4

Academic Journal

Anemia in renal allograft recipients ; Анемия у реципиентов аллотрансплантированных почек

Συγγραφείς: V. A. Goryainov, M. M. Kaabak, L. A. Shishlo, N. N. Babenko, M. M. Morozov, В. А. Горяйнов, М. М. Каабак, Л. А. Шишло, Н. Н. Бабенко, М. М. Морозова

Πηγή: Transplantologiya. The Russian Journal of Transplantation; № 1 (2010); 54-57 ; Трансплантология; № 1 (2010); 54-57 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2010-0-1

Θεματικοί όροι: миелотоксичность, posttransplantation anemia, erythropoietin, immunosuppression, myelotoxicity, посттрансплантационная анемия, эритропоэтин, иммунодепрессия

Περιγραφή αρχείου: application/pdf

Relation: https://www.jtransplantologiya.ru/jour/article/view/270/333; Vanrenterghem Y., Ponticelly C., Morales J.M. et al. Prevalence and management of anemia in renal transplants recipients: a European survey. Am J Transplant 2003;3:835–45.; Augustine J.J., Hricik D.E. Anemia after kidney transplantation: time for action. J Am Soc Nephrol 2006;17:2962–3.; Bagga A., Hari P., Moudgil A. et al. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephritic syndrome. Am J Kidney Dis 2003;42:1114–20.; Filler G., Gripas R., Mai I et al. Pharmacokinetics of tacrolimus (FK506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997;12:1668–71.; Gouva C., Nikolopoulos P., Ioanidis J.P. et al. Treating anemia early in renal failure patients slows the decline of renal function; a randomized controlled trial. Kidney Dis 2004;66:753–60.; Kolonko A., Pinoci-Mandok J., Kocierz M. et al. Anemia and erythrocytosis after kidney transplantation: 5-year graft function and survival analysis. Transplant Proc 2009;41(8):3046–51.; Mahmud S.N., Aziz R., Akhtar F. et al. Anemia characteristics after renal transplantation. Transplant Proc 2002;34:24–8.; Moore J., Cockwell P., Little M.A. et al. The impact of hemoglobin levels on patient and graft survival in renal transplant recipients. Transplantation 2008;86(4):564–70.; Mitsnefes M.M., Subat-Dezulovic M., Khoury P.R. et al. Increasing incidence of post-kidney transplant anemia in children. Am J Transplant 2005;5:1713–8.; Ponticelli C., Villa M. Role of anemia in cardiovascular mortality and morbidity in transplant patients. Nephrol Dial Transplant 2002;17(Suppl 1):41–6.; Rossert J., Fouqueray B., Boffa J.J. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003;14:173–7.; Turkowski-Duhem A., Kamar N., Cointault O. et al. Predictive factors of anemia within the first year post renal transplant. Transplantation 2005;7:903–9.; Van Biesen W., Vanholder R., Neys N. et al. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005;79(3):367–8.; Winkelmayer W.C., Kewalramani R., Rutstein M. et al. Pharmacoepidemiology of anemia in renal transplant recipients. J Am Soc Nephrol 2004;15:1347–52.; Yorgin P.D., Scandling J.D., Belson A. et al. Late post-transplant anemia in adult renal transplant recipients. An underrecognized problem? Am J Transplant 2002;2:429–35.; Al-Uzri A., Yorgin P.D., Kling P.J. Anemia and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 2003;7:253–64.; Hricik D.E. Anemia after kidney transplantation: Is the incidence increasing? Am J Transplant 2003;3:771–2.; Kamar N., Rostaying L. Negative impact of one-year anemia on long-tern patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycofenolate mofetil. Transplantation 2008;85(8):1120–4.; Ersoy A., Kahvecioglu S., Ersoy C. et al. Anemia due to losartan in hypertensive renal transplant recipients without positive influence on blood pressure. Transplant Proc 2005;37:2148–50.; Kasiske B.L., Vazquez M.A., Harmon W.E. et al. Recommendations for the outpatient surveillance of renal of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000;11(Suppl 15):1–86.; Kim H.C., Park S.B., Han S.Y. et al. Anemia following renal transplantation. Transplant Proc 2003;35(1):302.; Wilfingseder J., Kainz A., Perco P. et al. Molecular predictors for anemia after kidney transplantation. Nephrol Dial Transplant 2009;24(3):1015–23.; Schwartz G.J., Gautier B.A. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985;106:522–6.; Philipp S., Ollmann H., Schink T. et al. The impact of anemia and kidney function in congestive heart failure and preserved systolic function. Nephrol Dial Transplant 2005;20:915–9.; Shah N., Al-khoury S., Afzali B. et al. Posttransplant anemia in adults renal allograft recipients: prevalence and predictors. Transplantation 2006;81(8):1112–8.; Imoagene-Oyedeji A.E., Rosas S.E., Doyle A.M. et al. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol 2006;17:3240–7.; Thaunat O., Beaumont C., Chatenoud L. et al. Anemia after late introduction of cirolimus may correlate with biochemical levidence of a chronic inflammatory state. Transplantation 2005;80(9):1212–9.; Weiner D.E., Tighiouart H., Vlagopulos P.T. et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16:1803–10.; Zadrail J., Horak P., Horika V. et al. Endogenous erythropoietin levels and anemia in long-term transplant recipients. Kidney Blood Press. Res 2007;30(30):106–16.; Choukroun G., Deray G., Glotz D. et al. Incidence and management of anemia in renal transplantation : an observational-french study. Nephrol Ther 2008;4(7):575–83.; Chhabra D., Grafals M., Scaro A.I. et al. Impact of anemia after renal transplantation on patients and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 2008;3:1168–74.; Becker B.N., Becker I.T., Leverson G.E. et al. Erythropoietin therapy may retard progression in chronic renal transplant disfunction. Nephrol Dial Transplant 2002;17:1667–73.; Kahng K., Kang C., Kwak J. Changes in hemoglobin levels after renal transplantation. Transplant Proc 1998;30:3023–4.; Mix T.C., Kazmi W., Khan S. et al. Anemia: A continuing problem following kidney transplantation. Am J Transplant 2003;3:1426–33.; Vanrenterghem I. Anemia after kidney transplantation. Transplantation 2009;87(9):1265–7.; Augustine J.J., Knauss T.C., Schulak J.A. et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004;4:2001–6.; Yorgin P.D., Belson A., Sanchez J. et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002;40:1306–18.; Afzali B., Al-Khoury S., Mikhail A. et al. Anemia after renal transplantation. Am J Kidney Dis 2006;48(4):519–36.; Sistani S., Gruber S., Amm J. et al. Anemia after kidney transplantation (KT): prevalence and risk factors. Transplantation 2004;78(2):287.; Mohanram A., Zhang Z., Shahinfar S. et al. Anemia and end-stage renal disease in patients renal disease in patients with type-2 diabetes and nephropathy. Kidney Int 2004;66:1131–8.; https://www.jtransplantologiya.ru/jour/article/view/270

Διαθεσιμότητα: https://www.jtransplantologiya.ru/jour/article/view/270
https://doi.org/10.23873/2074-0506-2010-0-1-54-57

View record from BASE

5

Academic Journal